West Pharma (WST) Misses Q4 EPS by 1c; Issues Light FY15 EPS Outlook
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $334.00 +1.30%
Revenue Growth %: +9.5%
Financial Fact:
Income tax expense: 14.4M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +9.5%
Financial Fact:
Income tax expense: 14.4M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q4 EPS of $0.45, $0.01 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $349.8 million versus the consensus estimate of $348.33 million.
West Pharma sees FY2015 EPS of $1.74-$1.92, versus the consensus of $1.97. West Pharma sees FY2015 revenue of $1.43-1.46 billion, versus the consensus of $1.48 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
